TRPM8 Agonist (Cryosim-1) Cream for Chronic Prurigo: A Randomized, Vehicle-controlled Trial.

Summary

In a 30-patient randomized, double-blind, vehicle-controlled trial, Cryosim-1 cream (0.1% and 0.5%) significantly reduced Prurigo Activity Score, itch intensity, and improved DLQI, TEWL, and stratum corneum hydration over 4 weeks. The 0.1% formulation had superior tolerability with fewer stinging/erythema reports, supporting TRPM8-targeted topical therapy for chronic prurigo.

Key Findings

• Both 0.1% and 0.5% Cryosim-1 significantly reduced Prurigo Activity Score versus vehicle; 0.1% mean reduction −7.3 (p<0.001).
• Clinically meaningful improvements in 24-h itch intensity, DLQI, TEWL, and stratum corneum hydration over 4 weeks.
• 0.1% Cryosim-1 had better tolerability with fewer reports of stinging and erythema than 0.5%.

Clinical Implications

TRPM8-targeted topical therapy may offer a non-steroidal option for chronic prurigo; the 0.1% formulation balances efficacy and tolerability. Short-term barrier improvements (lower TEWL, higher hydration) suggest potential synergy with emollient regimens.

Limitations

• Small sample size (n=30) and short duration (4 weeks) limit generalizability and durability assessment.
• Single study without active comparator; long-term safety and relapse rates are unknown.

Future Directions

Conduct multicenter, longer-duration RCTs with active comparators, dose-ranging, and mechanistic biomarkers to confirm efficacy, safety, and durability.